**Table 8A.9.2:** Demographic Descriptive Statistics by Soft Tissue Cancer Type, by Age, United States, 1998-2011

| | | Age Category (N (% in Age Group)) | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Type | Total N | 18-29 | 30-39 | 40-49 | 50-59 | 60-69 | 70-79 | 80+ |
| Malignant Tumor, spindle cell type; Sarcoma, NOS; Spindle cell sarcoma; Undifferentiated sarcoma; Stromal sarcoma, NOS | 13979 | 833 (6.0%) | 1043 (7.5%) | 1733 (12.4%) | 2457 (17.6%) | 2592 (18.5%) | 2874 (20.6%) | 2447 (17.5%) |
| Fibrous histiocytoma, malignant | 13289 | 281 (2.1%) | 590 (4.4%) | 1312 (9.9%) | 2136 (16.1%) | 2640 (19.9%) | 3379 (25.4%) | 2951 (22.2%) |
| Liposarcoma Myxoid | 4349 | 381 (8.8%) | 810 (18.6%) | 1082 (24.9%) | 856 (19.7%) | 579 (13.3%) | 409 (9.4%) | 232 (5.3%) |
| Liposarcoma, well differentiated | 4304 | 62 (1.4%) | 187 (4.3%) | 604 (14%) | 953 (22.1%) | 1081 (25.1%) | 913 (21.2%) | 504 (11.7%) |
| Synovial sarcoma (NOS, spindle cell epithelioid cell, biphasic) | 4175 | 1112 (26.6%) | 877 (21%) | 904 (21.7%) | 620 (14.9%) | 358 (8.6%) | 207 (5.0%) | 97 (2.3%) |
| Giant cell sarcoma | 4141 | 89 (2.1%) | 189 (4.6%) | 413 (10%) | 810 (19.6%) | 919 (22.2%) | 945 (22.8%) | 776 (18.7%) |
| Malignant peripheral nerve sheath tumor; Neurilemmoma, malignant; MPNST with rhabdomyoblastic differentiation | 3827 | 691 (18.1%) | 680 (17.8%) | 723 (18.9%) | 646 (16.9%) | 471 (12.3%) | 376 (9.8%) | 240 (6.3%) |
| Hemangiosarcoma | 3471 | 92 (2.7%) | 138 (4.0%) | 261 (7.5%) | 472 (13.6%) | 684 (19.7%) | 932 (26.9%) | 892 (25.7%) |
| Liposarcoma, NOS | 2876 | 48 (1.7%) | 163 (5.7%) | 380 (13.2%) | 604 (21%) | 639 (22.2%) | 641 (22.3%) | 401 (13.9%) |
| Dermatofibrosarcoma, NOS; Pigmented dermatofibrosarcoma protuberans | 2776 | 459 (16.5%) | 684 (24.6%) | 693 (25%) | 515 (18.6%) | 221 (8.0%) | 147 (5.3%) | 57 (2.1%) |
| Fibromyxosarcoma | 2356 | 204 (6.1%) | 289 (8.6%) | 459 (13.7%) | 642 (19.1%) | 664 (19.8%) | 593 (17.7%) | 505 (15%) |
| Fibrosarcoma, NOS | 2102 | 202 (9.6%) | 264 (12.6%) | 366 (17.4%) | 374 (17.8%) | 314 (14.9%) | 352 (16.7%) | 230 (10.9%) |
| Liposarcoma Dedifferentiated | 1768 | 16 (0.9%) | 47 (2.7%) | 180 (10.2%) | 342 (19.3%) | 452 (25.6%) | 429 (24.3%) | 302 (17.1%) |
| Liposarcoma Pleomorphic | 1711 | 33 (1.9%) | 71 (4.1%) | 179 (10.5%) | 342 (20%) | 403 (23.6%) | 428 (25%) | 255 (14.9%) |
| Ewing sarcoma; Peripheral neuroectodermal tumor; Askin tumor; Primitive neuroectodermal tumor | 1496 | 666 (44.5%) | 309 (20.7%) | 242 (16.2%) | 141 (9.4%) | 70 (4.7%) | 49 (3.3%) | 19 (1.3%) |
| Epithelioid sarcoma | 1155 | 241 (20.9%) | 198 (17.1%) | 207 (17.9%) | 195 (16.9%) | 124 (10.7%) | 115 (10%) | 75 (6.5%) |
| Chondrosarcoma Myxoid | 854 | 34 (4.0%) | 93 (10.9%) | 165 (19.3%) | 200 (23.4%) | 186 (21.8%) | 114 (13.3%) | 62 (7.3%) |
| Chondrosarcoma, NOS | 581 | 41 (7.1%) | 70 (12.0%) | 82 (14.1%) | 121 (20.8%) | 108 (18.6%) | 113 (19.4%) | 46 (7.9%) |
| Hemangiopericytoma, malignant | 566 | 27 (4.8%) | 70 (12.4%) | 100 (17.7%) | 132 (23.3%) | 112 (19.8%) | 88 (15.5%) | 37 (6.5%) |
| Pleomorphic rhabdomyosarcoma, adult type | 566 | 24 (4.2%) | 38 (6.7%) | 69 (12.2%) | 102 (18%) | 134 (23.7%) | 111 (19.6%) | 88 (15.5%) |
| Osteosarcoma, NOS; Chondroblastic osteosarcoma; Fibroblastic osteosarcoma | 562 | 49 (8.7%) | 42 (7.5%) | 75 (13.3%) | 122 (21.7%) | 112 (19.9%) | 98 (17.4%) | 64 (11.4%) |
| Myxosarcoma | 558 | 14 (2.5%) | 36 (6.5%) | 88 (15.8%) | 105 (18.8%) | 109 (19.5%) | 109 (19.5%) | 97 (17.4%) |
| Rhabdomyosarcoma, NOS | 555 | 130 (23.4%) | 65 (11.7%) | 51 (9.2%) | 89 (16.0%) | 80 (14.4%) | 86 (15.5%) | 54 (9.7%) |
| Liposarcoma Mixed Type | 550 | 22 (4.0%) | 72 (13.1%) | 113 (20.5%) | 120 (21.8%) | 99 (18.0%) | 79 (14.4%) | 45 (8.2%) |
| Clear cell sarcoma, NOS (except of kidney) | 542 | 116 (21.4%) | 111 (20.5%) | 105 (19.4%) | 89 (16.4%) | 51 (9.4%) | 44 (8.1%) | 26 (4.8%) |
| Liposarcoma Round cell | 460 | 29 (6.3%) | 94 (20.4%) | 126 (27.4%) | 92 (20.0%) | 59 (12.8%) | 42 (9.1%) | 18 (3.9%) |
| Rhabdomyosarcoma Alveolar | 384 | 226 (58.9%) | 52 (13.5%) | 40 (10.4%) | 26 (6.8%) | 17 (4.4%) | 16 (4.2%) | 7 (1.8%) |
| Alveolar soft part sarcoma | 340 | 209 (61.5%) | 69 (20.3%) | 30 (8.8%) | 20 (5.9%) | 6 (1.8%) | 6 (1.8%) | 15 (4.5%) |
| Small cell sarcoma | 310 | 78 (25.2%) | 50 (16.1%) | 57 (18.4%) | 60 (19.4%) | 31 (10.0%) | 18 (5.8%) | 16 (5.2%) |
| Solitary fibrous tumor, malignant | 305 | 12 (3.9%) | 19 (6.2%) | 39 (12.8%) | 64 (21.0%) | 68 (22.3%) | 69 (22.6%) | 34 (11.1%) |
| Desmoplastic small round cell tumor | 296 | 169 (57.1%) | 72 (24.3%) | 36 (12.2%) | 9 (3.0%) | 4 (1.4%) | 5 (1.7%) | 1 (0.3%) |
| Rhabdomyosarcoma Embryonal | 277 | 107 (38.6%) | 44 (15.9%) | 40 (14.4%) | 31 (11.2%) | 28 (10.1%) | 14 (5.1%) | 13 (4.7%) |
| Epithelioid hemangioendothelioma, malignant | 213 | 23 (10.8%) | 35 (16.4%) | 53 (24.9%) | 43 (20.2%) | 28 (13.1%) | 26 (12.2%) | 5 (2.3%) |
| Mesenchymal chondrosarcoma | 134 | 36 (26.9%) | 33 (24.6%) | 20 (14.9%) | 16 (11.9%) | 12 (9.0%) | 11 (8.2%) | 6 (4.5%) |
| Malignant myoepithelioma | 108 | 17 (15.7%) | 20 (18.5%) | 20 (18.5%) | 18 (16.7%) | 10 (9.3%) | 11 (10.2%) | 12 (11.1%) |
| Mesenchymoma, malignant | 90 | 15 (16.7%) | 10 (11.1%) | 14 (15.6%) | 15 (16.7%) | 10 (11.1%) | 15 (16.7%) | 11 (12.2%) |
| Merkel cell carcinoma | 79 | 0 (0.0%) | 1 (1.3%) | 9 (11.4%) | 10 (12.7%) | 19 (24.1%) | 18 (22.8%) | 22 (27.8%) |
| Granular cell tumor, malignant | 71 | 8 (11.3%) | 9 (12.7%) | 14 (19.7%) | 18 (25.4%) | 15 (21.1%) | 5 (7.0%) | 2 (2.8%) |

Source: American College of Surgeons National Cancer Data Base (NCDB).
NOTE: NCDB Adult Soft Tissue Sarcoma Data Summary

Demographic data is available on cases diagnosed from 1998 – 2011. A total of 91,163 cases were available. Mortality is only available from 44,065 cases reported 1998 – 2006. The sample size by cancer type is provided in the tables. The difference in sample size is related to excluding cases without followup data. Per NCDB, mortality data is not available for the last five years of collection (2007-2011). Also, per NCDB, cases were excluded if they had multiple cancer types. Note that this data set only included patients 18 years old and older. Data on children with cancer was not available for this analysis.

The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in this study and this report are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator and authors of this work.